Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-Current Deffered Revenue (2019 - 2025)

Historic Non-Current Deffered Revenue for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $14.0 million.

  • Kymera Therapeutics' Non-Current Deffered Revenue changed N/A to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year change of. This contributed to the annual value of $16.8 million for FY2023, which is 4011.43% down from last year.
  • As of Q3 2025, Kymera Therapeutics' Non-Current Deffered Revenue stood at $14.0 million.
  • Kymera Therapeutics' 5-year Non-Current Deffered Revenue high stood at $64.7 million for Q1 2021, and its period low was $3.2 million during Q2 2024.
  • Its 5-year average for Non-Current Deffered Revenue is $28.7 million, with a median of $24.1 million in 2022.
  • Data for Kymera Therapeutics' Non-Current Deffered Revenue shows a peak YoY increase of 436.34% (in 2024) and a maximum YoY decrease of 8438.37% (in 2024) over the last 5 years.
  • Over the past 5 years, Kymera Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $39.3 million in 2021, then decreased by 28.74% to $28.0 million in 2022, then tumbled by 40.11% to $16.8 million in 2023, then crashed by 80.98% to $3.2 million in 2024, then skyrocketed by 337.66% to $14.0 million in 2025.
  • Its Non-Current Deffered Revenue was $14.0 million in Q3 2025, compared to $3.2 million in Q2 2024 and $23.8 million in Q1 2024.